Cue Biopharma, Inc.CUENASDAQ
Loading
CUE Revenue Growth (YoY Quarterly)•+1292.26%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+1292.26%
+1327.8pp
+1088.83%
+1126.8pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+45.46%
-51.4pp
+48.86%
-48.0pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -13.45% | -75.48% | +11.14% | -35.58% | +1292.26% |
| Gross Profit Growth | +0.00% | -75.48% | +11.14% | -37.95% | +1088.83% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +57.47% | +50.11% | +90.25% | +96.90% | +45.46% |
| Weighted Average Shares Diluted Growth | +57.47% | +50.11% | +90.25% | +96.90% | +48.86% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -44.35% | -100.00% | -71.20% | -27.47% | +486.88% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -47.68% | -58.75% | -3.83% | -29.38% | +31.13% |
| Book Value per Share Growth | -70.03% | -85.41% | -55.86% | -73.48% | +3.84% |
| Debt Growth | -39.60% | -45.18% | -32.22% | -35.10% | -52.72% |
| R&D Expense Growth | -34.01% | -16.20% | -17.00% | -50.05% | +130.12% |
| SG&A Expenses Growth | +100.15% | +25.05% | +4.67% | +71.89% | -14.15% |
1 / 4